Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy
Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy
批准号:
10203557
负责人:
Nina Bhardwaj
金额:
$16.84万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2023-06-30
关键词:
2019-nCoVAffectCD4 Lymphocyte CountCD8-Positive T-LymphocytesCOVID-19Cancer PatientCell CompartmentationCellsCessation of lifeClinicalClinical/RadiologicDataDiseaseFunctional disorderImmune checkpoint inhibitorImmune systemImmunotherapyIndividualInfectionMalignant NeoplasmsMetastatic MelanomaNatural Killer CellsPD-1 blockadePatientsPhenotypePneumoniaPopulationRadiologic FindingRecording of previous eventsRecoveryRegimenResolutionSeveritiesSolid NeoplasmT-LymphocyteTumor SuppressionVirus Diseasescancer immunotherapychemotherapycohortexhaustexhaustionexperiencehigh riskmelanomapalliationpandemic diseaseperipheral bloodprogrammed cell death protein 1receptorresponse
中文摘要
由SARS-CoV-2引起的大流行在6个月的时间里已导致全球43万人死亡
总体而言,癌症患者感染后患重病和死亡的风险更高,尽管
不同的治疗方案是可能的(例如,化疗、免疫治疗和姑息治疗)。癌症患者
从新冠肺炎康复的人可能需要恢复治疗,包括对他们的疾病进行免疫治疗
尽管这种感染对他们的免疫系统的影响尚不清楚。这个项目将决定
如果从新冠肺炎康复的癌症患者具有与癌症不同功能的NK细胞
未感染的患者,以及这些表型是否对总应答率和
这群人的生存。
英文摘要
The pandemic caused by SARS-CoV-2 has killed 430,000 people worldwide in the span of 6 months which
overall place cancer patients at a higher risk of severe illness and death if infected, although differences between
distinct therapy regimens are possible (e.g. chemotherapy vs. immunotherapy vs. palliation). Cancer patients
who have recovered from COVID-19 may need to resume treatment, including immunotherapy for their disease
even though the repercussions of this infection on their immune systems are unknown. This project will determine
if cancer patients who have recovered from COVID-19 have NK cells with different functionality than cancer
patients who were not infected, and whether these phenotypes have an impact on the overall response rate and
survival of this population.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.ucl.2020.07.002
发表时间:
2020-11
期刊:
The Urologic clinics of North America
影响因子:
--
作者:
[Bhardwaj N, Farkas AM, Gul Z, Sfakianos JP]
通讯作者:
Sfakianos JP
DOI:
10.1038/s41467-018-05992-x
发表时间:
2018-08-29
期刊:
Nature communications
影响因子:
16.6
作者:
[Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD]
通讯作者:
Galsky MD
DOI:
10.1016/j.urolonc.2020.06.007
发表时间:
2022-09
期刊:
Urologic oncology
影响因子:
--
作者:
[Attalla K, Farkas AM, Anastos H, Audenet F, Galsky MD, Bhardwaj N, Sfakianos JP]
通讯作者:
Sfakianos JP
The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology
-
批准号:10434380
-
项目类别:
-
资助金额:$5.4万
-
财政年份:2022
-
负责人:Nina Bhardwaj
-
依托单位:
The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology
-
批准号:10623252
-
项目类别:
-
资助金额:$56.69万
-
财政年份:2022
-
负责人:Nina Bhardwaj
-
依托单位:
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer
-
批准号:10652272
-
项目类别:
-
资助金额:$68.93万
-
财政年份:2020
-
负责人:Nina Bhardwaj
-
依托单位:
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer
-
批准号:10380068
-
项目类别:
-
资助金额:$68.93万
-
财政年份:2020
-
负责人:Nina Bhardwaj
-
依托单位:
NK cell exhaustion in metastatic melanoma
-
批准号:9177359
-
项目类别:
-
资助金额:$40.36万
-
财政年份:2016
-
负责人:Nina Bhardwaj
-
依托单位:
Cancer Immunology
-
批准号:10454170
-
项目类别:
-
资助金额:$2.63万
-
财政年份:2015
-
负责人:Nina Bhardwaj
-
依托单位:
Cancer Immunology (CI) (Project-001)
-
批准号:8932191
-
项目类别:
-
资助金额:$0.93万
-
财政年份:2015
-
负责人:Nina Bhardwaj
-
依托单位:
Cancer Immunology
-
批准号:10674510
-
项目类别:
-
资助金额:$2.63万
-
财政年份:2015
-
负责人:Nina Bhardwaj
-
依托单位:
Cancer Immunology
-
批准号:10022663
-
项目类别:
-
资助金额:$2.63万
-
财政年份:2015
-
负责人:Nina Bhardwaj
-
依托单位:
Matrix metalloproteinase-2 modulates inflammation via TLR2
-
批准号:8777819
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2014
-
负责人:Nina Bhardwaj
-
依托单位:
Matrix metalloproteinase-2 modulates inflammation via TLR2
-
批准号:8874174
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2014
-
负责人:Nina Bhardwaj
-
依托单位:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
-
批准号:8744629
-
项目类别:
-
资助金额:$33.86万
-
财政年份:2013
-
负责人:Nina Bhardwaj
-
依托单位:
Induction of Immunity by Non-Replicating HIV-1
-
批准号:8744626
-
项目类别:
-
资助金额:$22.12万
-
财政年份:2013
-
负责人:Nina Bhardwaj
-
依托单位:
NIAID Clinical Trial Planning Grant
-
批准号:8211593
-
项目类别:
-
资助金额:$28.61万
-
财政年份:2011
-
负责人:Nina Bhardwaj
-
依托单位:
Innate Discovery Team
-
批准号:8294657
-
项目类别:
-
资助金额:$120.4万
-
财政年份:2011
-
负责人:Nina Bhardwaj
-
依托单位:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
-
批准号:8240408
-
项目类别:
-
资助金额:$41.83万
-
财政年份:2010
-
负责人:Nina Bhardwaj
-
依托单位:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
-
批准号:8436297
-
项目类别:
-
资助金额:$39.31万
-
财政年份:2010
-
负责人:Nina Bhardwaj
-
依托单位:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
-
批准号:8058751
-
项目类别:
-
资助金额:$41.83万
-
财政年份:2010
-
负责人:Nina Bhardwaj
-
依托单位:
Exposing virus-induced long noncoding RNA in plasmacytoid dendritic cells
-
批准号:10239219
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2010
-
负责人:Nina Bhardwaj
-
依托单位:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
-
批准号:8651406
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2010
-
负责人:Nina Bhardwaj
-
依托单位:
海外基金